Adenoviral Interleukin 24 (Ad-IL24) for Advanced Melanoma (MultiVir Study Ad-IL24-001)

The MultiVir Ad-IL24-001 trial will be conducted to evaluate the safety and efficacy of investigational Ad-IL24 in patients with advanced melanoma that have progressed on standard treatments.

In this trial, Ad-IL24 will be injected into melanoma tumors. The Ad-IL24 investigational treatment will be combined with an approved cancer therapy termed anti-PD-1 that may have complementary immune stimulating activity.

Studies performed in animal tumor models suggest that Ad-IL24 may enhance the anti-tumor effects of anti-PD-1.